新里程健康科技集团股份有限公司 投资者关系活动记录表 编号：2024-04 | --- | --- | --- | |------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关系 | □ 媒体采访 | 业绩说明会 | | 活动类别 | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | | | 兴业证券、海通证券、中信建投、东吴证券、天风证券、中信证券、 | | | | 中金公司、申万宏源、广发证券、西南证券、华安证券、首创证券、 | | | | 华鑫证券、湘财证券、中邮证券、华创证券、信达证券、招商证券、 | | | | 平安证券、光大证券、华泰证券、民生证券、东北证券、国联证券、 | | | | 国海证券、国盛 ...

Investment Rating - The report assigns a "Buy" rating to the company, with a first-time coverage [2] Core Views - The company's hospital segment showed steady growth in H1 2024, with revenue increasing by 12.20% YoY to RMB 1.82 billion and net profit attributable to shareholders rising by 5.27% YoY to RMB 60 million [3] - The company's core hospitals demonstrated strong performance, with Wafangdian Third Hospital achieving an 8% YoY revenue growth to RMB 330 million and Lankao First Hospital growing 2.5% YoY to RMB 220 million [3] - The company's existing hospitals have high local market share and strong profitability, with a net profit margin of 9% in 2023 [4] - The company is expanding through new beds and asset injections, with plans to add 600 beds at Xuyi Hospital and 800 beds at Chongzhou Second Hospital [5] - The controlling shareholder plans to inject high-quality medical assets into the company within 5 years, potentially doubling the company's asset scale [6] Financial Performance - In H1 2024, the company's medical service revenue grew 2.98% YoY to RMB 1.45 billion, while pharmaceutical revenue surged 72.63% YoY to RMB 371 million [3] - The company's gross margin declined by 3.43 percentage points to 29.06% in H1 2024, mainly due to changes in business structure after acquiring Furen [3] - Operating cash flow increased by 15.5% YoY to RMB 145 million in H1 2024, while investment cash flow was -RMB 168 million and financing cash flow was -RMB 84 million [3] Expansion Plans - The company is actively expanding its hospital network, with new projects adding nearly 10,000 beds and existing bed utilization rate at around 90% [4] - Xuyi Hospital's new oncology building, adding 600 beds, started construction in October 2023, while Chongzhou Second Hospital's new 800-bed facility is expected to open in early 2025 [5] - Lankao First Hospital is preparing to establish a tumor center, and Siyang Hospital has obtained a license for a geriatric hospital and is applying for a tumor hospital license [6] Financial Projections - The company's revenue is expected to grow from RMB 4.105 billion in 2024 to RMB 5.838 billion in 2026, with net profit attributable to shareholders projected to increase from RMB 114.79 million to RMB 352.11 million [7][9] - EPS is forecasted to rise from RMB 0.03 in 2024 to RMB 0.10 in 2026, with P/E ratios decreasing from 51.67x to 16.84x over the same period [7][9] - The company's gross margin is expected to remain stable at around 29.5%-29.9% from 2024 to 2026, with net profit margin increasing from 2.8% to 6.0% [11]

Investment Rating - The report assigns a "Hold" rating for the company [6] Core Insights - The company achieved a revenue growth of 12.20% year-on-year in H1 2024, with a net profit growth of 5.27% [2] - The company is expected to inject high-quality external hospital assets in the future, which could enhance its operational capacity and market position [6] Financial Performance - In H1 2024, the company reported revenue of 1.82 billion yuan, a 12.20% increase year-on-year, and a net profit of 60 million yuan, up 5.27% [2] - The second quarter of 2024 saw revenue of 957 million yuan, reflecting a 14.41% year-on-year growth, while net profit was 36 million yuan, a 1.02% increase [2] - The company's gross margin for H1 2024 was 29.06%, down 3.71 percentage points from the previous year, and the net margin was 3.42%, down 0.34 percentage points [3] Cost Management - The company's management expense ratio decreased significantly to 14.46%, down 2.94 percentage points year-on-year, attributed mainly to reduced equity incentive costs [3] - The financial expense ratio increased to 3.41%, up 0.18 percentage points year-on-year [3] Healthcare Services - The healthcare services segment generated revenue of 1.45 billion yuan in H1 2024, a 2.98% increase year-on-year [4] - The company plans to expand its bed capacity, with several new hospital projects underway, including a new oncology specialty building and a new hospital district [4] Pharmaceutical Business - The pharmaceutical and medical products segment achieved revenue of 371 million yuan in H1 2024, a remarkable 72.63% increase year-on-year [5] - The company is leveraging its well-known "Duyiwei" brand to develop a line of oral care products, entering the fast-moving consumer goods market [5] Future Projections - Revenue projections for 2024-2026 are estimated at 3.993 billion yuan, 4.400 billion yuan, and 4.835 billion yuan, respectively, with net profits expected to be 128.2 million yuan, 184.1 million yuan, and 237.7 million yuan [6][7]

本报告仅供 Choice 东方财富 使用，请勿传阅。 2024 年 08 月 23 日 新里程(002219.SZ) 主营业务平稳，重点关注定增进度 事件： 2024 年 8 月 21 日，公司发布 2024 年中期报告。2024 年上半年公 司实现营业收入 18.20 亿元，同比增长 12.20%；实现归母净利润 0.60 亿元，同比增长 5.27%；实现扣非归母净利润 0.59 亿元，同比 增长 18.46%。单季度来看，2024 年 Q2 公司实现营业收入 9.57 亿 元，同比增长 14.41%；实现归母净利润 0.36 亿元，同比增长 1.02%； 实现扣非归母净利润 0.34 亿元，同比增长 15.40%。 医疗服务板块保持平稳，医药板块积极拓展增量。 公司坚持"医疗+医药"双轮驱动的经营模式：1）公司医疗服务板块 保持平稳，2024 年 H1 实现营业收入 14.50 亿元，同比增长 2.98%， 其中，瓦房店第三医院子公司实现营业收入 3.30 亿元，兰考第一医 院子公司实现营业收入 2.21 亿元，泗阳县人民医院子公司实现营业 收入 3.05 亿元。2）公司医药板块积极拓展增量，2024 年 ...

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-073 新里程健康科技集团股份有限公司 第六届监事会第十九次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第六 届监事会第十九次会议通知于2024年8月12日以书面、电子邮件、电话送达等方 式发出，会议于2024年8月22日以现场表决结合通讯方式表决在公司会议室召开。 会议由公司监事会主席李海涛先生召集并主持，公司现任监事3名，实际表决监 事3名，符合《公司法》和《公司章程》的有关规定，会议决议合法有效。 二、监事会会议审议情况 经与会监事审议，会议审议通过了以下议案并做出如下决议： （一）审议通过《关于公司<2024 年半年度报告>及<2024 年半年度报告摘 要>的议案》 经审核，监事会认为董事会编制和审核的新里程健康科技集团股份有限公司 《2024年半年度报告》及《2024年半年度报告摘要》的程序符合法律、行政法规 和中国证监会的规定，报告内容真实、准确、完整地 ...

新里程健康科技集团股份有限公司 一、董事会会议召开情况 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第六 届董事会第二十五次会议于 2024 年 8 月 12 日以书面、电话、电子邮件等形式发 出，会议于 2024 年 8 月 22 日在公司会议室以现场表决结合通讯表决的方式召开， 本次会议由公司董事长林杨林先生主持，公司现任董事 11 名，实际表决董事 11 名，公司监事及高级管理人员列席本次会议，会议的召开与表决程序符合《公司 法》和《公司章程》的有关规定，所做决议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，审议通过了以下议案并形成决议。 （一）审议通过《关于公司<2024 年半年度报告>及<2024 年半年度报告摘 要>的议案》 经审议，公司《2024年半年度报告》及《2024年半年度报告摘要》内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏，同意《关于公司<2024年半年度报告>及<2024年半年度报告摘要>的议 案》。 证券简称：新里程 证券代码：002219 公告编号：2024-072 新里程健康科技集团股份有限公司 第六届董 ...

新里程健康科技集团股份有限公司2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：新里程健康科技集团股份有限公司 | | | | | | | | | 金额单位：人民币万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 资金占用方名称 占用方与上市公司的 | 上市公司核算的会 | 2024年期初占用资 | 2024年半年度占用累计发生 | 2024年半年度占用资金 | 2024年半年度偿还 | 2024年半年度末占 | 占用形成原因 | 占用性质 | | | | 关联关系 | 计科目 | 金余额 | 金额（不含利息） | 的利息（如有） | 累计发生金额 | 用资金余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | - ...

Financial Performance - The company's operating revenue for the reporting period was CNY 1,820,242,878.06, representing a 12.20% increase compared to the previous year's CNY 1,606,723,364.98[11] - The net profit attributable to shareholders of the listed company was CNY 60,144,512.50, which is a 5.27% increase from CNY 57,004,556.73 in the same period last year[11] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 58,555,051.85, marking an 18.46% increase from CNY 49,304,434.47 in the previous year[11] - The net cash flow from operating activities was CNY 144,585,899.24, up 15.50% from CNY 125,210,313.12 in the same period last year[11] - The company achieved a consolidated revenue of CNY 1.82 billion in the first half of 2024, representing a year-on-year growth of 12.20%[21] - The net profit for the period was CNY 62.31 million, with a net profit attributable to shareholders of CNY 60.14 million, reflecting a year-on-year growth of 5.27%[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,304,292,218.43, reflecting a 3.69% increase from CNY 6,080,204,990.53 at the end of the previous year[11] - The net assets attributable to shareholders of the listed company were CNY 2,306,984,135.12, which is a 5.07% increase from CNY 2,195,689,411.03 at the end of the previous year[11] - The asset-liability ratio decreased to 62.77%, down by 0.48 percentage points from the beginning of the year[21] - The company's total liabilities amounted to CNY 3,957,348,044.19, up from CNY 3,845,698,741.33, showing an increase of around 2.9%[71] Earnings and Shareholder Returns - The basic earnings per share for the reporting period was CNY 0.0176, a 2.92% increase from CNY 0.0171 in the same period last year[11] - The diluted earnings per share also stood at CNY 0.0176, reflecting the same 2.92% increase as the basic earnings per share[11] - The company plans not to distribute cash dividends or bonus shares for this reporting period[1] - The company plans not to distribute cash dividends or bonus shares for the first half of 2024[37] Market and Business Strategy - The company aims to enhance its market share and operational quality through strategic restructuring and scale expansion in its medical services business[16] - The company is focused on addressing the growing demand for healthcare services driven by an aging population and increasing chronic disease prevalence[17] - The company is actively expanding its market presence in the pharmaceutical sector, particularly in traditional Chinese medicine, and is exploring new business opportunities[21] - The company is focusing on a dual-driven strategy of "medical + pharmaceutical," with a clear direction for its subsidiaries in both sectors[21] Operational Developments - The company has established five regional medical centers in Liaoning, Henan, Jiangsu, Jiangxi, and Sichuan, with a total of 3 tertiary hospitals and 7 secondary hospitals[14] - The company added 6 new provincial and municipal key specialties during the reporting period, enhancing its medical service capabilities[21] - The company has implemented a refined management approach to enhance operational efficiency and service quality across its hospitals[21] Research and Development - The company is developing a new oral care product line leveraging the medicinal properties of its "Duyiwei" products, aiming to enter the fast-moving consumer goods market[16] - Research and development expenses increased significantly to ¥6,403,898.44, compared to ¥818,986.75 in the previous year, marking an increase of 681.5%[78] - The company plans to enhance its research and development efforts to innovate new technologies[97] Shareholder Structure and Governance - The company held its first extraordinary general meeting of 2024 on March 11, with a participation rate of 33.06%[34] - The annual general meeting on May 10, 2024, had a participation rate of 32.42%[34] - The company elected new directors, including Xue Ping as a non-independent director on March 11, 2024[36] - The company has implemented a stock incentive plan to attract and retain talent, aligning interests among shareholders, the company, and employees[38] Financial Management and Risks - The company faces risks related to policy changes in the healthcare sector, which may impact operations and profitability[32] - The company has assessed its ability to continue as a going concern for the next 12 months, indicating sufficient resources to maintain operations[110] - The company has a structured approach to accounting for lease payments, ensuring compliance with relevant accounting standards[171] Accounts Receivable and Bad Debts - Accounts receivable increased to ¥1,253,725,754.16, accounting for 19.89% of total assets, up by 3.06% from the previous year[27] - The total accounts receivable at the end of the period amounted to ¥1,585,619,180.08, with a bad debt provision of ¥331,893,425.92, resulting in a provision ratio of 20.92%[194] - The company has identified multiple accounts with a 100% expected unrecoverability rate, indicating a high risk of default across its receivables[193] Environmental and Legal Compliance - The company has not faced any administrative penalties related to environmental issues during the reporting period and complies with various environmental protection laws[43] - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[47] - The company has not engaged in any major related party transactions or non-operating fund occupation by controlling shareholders during the reporting period[47]

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-071 新里程健康科技集团股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）近日 接到公司控股股东北京新里程健康产业集团有限公司（以下简称"新里程集团" 或"控股股东"）函告并通过中国证券登记结算有限公司系统查询，获悉其所持 有本公司的部分股份解除质押及再质押，具体事项如下： 2．股东股份累计质押情况 截至公告披露日，控股股东所持质押股份情况如下： | 股东 | 是否为 控股股 | 本次解除质 押股份数量 | 占其所 持股份 | 占公司总 | 质押起 | 解除 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | | 股本比例 | 始日 | 日期 | | | | 东 | (股) | 比例 | | | | | | 新里程 | | 157,480,315 | 19.07% | ...

北京市中伦律师事务所 关于新里程健康科技集团股份有限公司 2024 年第四次临时股东大会的 法律意见书 二〇二四年八月 北京市中伦律师事务所 关于新里程健康科技集团股份有限公司 2024 年第四次临时股东大会的 法律意见书 致：新里程健康科技集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）受新里程健康科技集团股份有 限公司（以下简称"公司"）委托，指派律师出席公司 2024 年第四次临时股东 大会（以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股东大会规则》等相关法律、法规、 规范性文件及《新里程健康科技集团股份有限公司章程》（以下简称"《公司章 程》"）、《新里程健康科技集团股份有限公司股东大会议事规则》（以下简称 "《股东大会规则》"）的规定，对本次股东大会进行见证并出具法律意见。 经查验，根据公司第六届董事会第二十四次会议的决议，公司于 2024 年 8 月 2 日在指定媒体发布了《新里程健康科技集团股份有限公司关于召开 2024 年 第四次临时股东大会的通知》（以下简称"《会议通知》"）。本次会议由公司 董事会召集，《会议通知》的内容 ...